Company intelligence / Profile preview
Calgent Biotechnology
Taipei City, Taiwancalgent.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Preclinical
01
Overview
Calgent Biotechnology develops novel small molecule therapeutics targeting cancers—including colorectal and liver cancers—and inflammatory/immune diseases. Its lead asset CAL056 has Orphan Drug Designation for multiple myeloma and entered Phase I trials in the US after FDA IND approval in October 2020. Preclinical data show anti-tumor activity with low toxicity across several tumor types. The company leverages academic-industry collaborations from its roots as a Taipei Medical University spin-off to advance a pipeline of innovative drug candidates addressing unmet medical needs in oncology and immunology.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Precision medicine platform partnersuniversity-industry collaborations with Taipei Medical University.
Beyond the preview
Go deeper on Calgent Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calgent Biotechnology.